1. Home
  2. NBTB vs IMNM Comparison

NBTB vs IMNM Comparison

Compare NBTB & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NBT Bancorp Inc.

NBTB

NBT Bancorp Inc.

N/A

Current Price

$50.06

Market Cap

2.6B

Sector

Finance

ML Signal

N/A

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$19.53

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NBTB
IMNM
Founded
1856
2006
Country
United States
United States
Employees
2303
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.5B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
NBTB
IMNM
Price
$50.06
$19.53
Analyst Decision
Hold
Strong Buy
Analyst Count
7
16
Target Price
★ $57.50
$35.20
AVG Volume (30 Days)
316.9K
★ 1.3M
Earning Date
10-27-2026
11-05-2026
Dividend Yield
★ 3.17%
N/A
EPS Growth
12.12
★ 51.40
EPS
★ 1.99
N/A
Revenue
★ $182,952,000.00
$6,941,000.00
Revenue This Year
$8.99
N/A
Revenue Next Year
$5.53
$18,747.97
P/E Ratio
$25.39
★ N/A
Revenue Growth
★ 10.40
N/A
52 Week Low
$39.21
$13.53
52 Week High
$54.50
$30.06

Technical Indicators

Market Signals
Indicator
NBTB
IMNM
Relative Strength Index (RSI) 41.88 30.12
Support Level $49.75 $19.39
Resistance Level $51.09 $23.48
Average True Range (ATR) 0.77 1.12
MACD -0.05 -0.27
Stochastic Oscillator 29.02 13.81

Price Performance

Historical Comparison
NBTB
IMNM

About NBTB NBT Bancorp Inc.

NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: